[go: up one dir, main page]

MA44836A - Procédés de traitement du syndrome polykystique des reins - Google Patents

Procédés de traitement du syndrome polykystique des reins

Info

Publication number
MA44836A
MA44836A MA044836A MA44836A MA44836A MA 44836 A MA44836 A MA 44836A MA 044836 A MA044836 A MA 044836A MA 44836 A MA44836 A MA 44836A MA 44836 A MA44836 A MA 44836A
Authority
MA
Morocco
Prior art keywords
treatment methods
syndrome treatment
polycystic syndrome
kidney
kidney polycystic
Prior art date
Application number
MA044836A
Other languages
English (en)
Inventor
John R Androsavich
B Nelson Chau
Vishal D Patel
Original Assignee
Univ Texas
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA44836A publication Critical patent/MA44836A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés de traitement d'une maladie rénale polykystique, y compris une maladie rénale polykystique autosomique dominante, utilisant des oligonucléotides modifiés ciblés sur mir-17.
MA044836A 2015-08-26 Procédés de traitement du syndrome polykystique des reins MA44836A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210031P 2015-08-26 2015-08-26

Publications (1)

Publication Number Publication Date
MA44836A true MA44836A (fr) 2018-07-04

Family

ID=56855838

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044836A MA44836A (fr) 2015-08-26 Procédés de traitement du syndrome polykystique des reins

Country Status (14)

Country Link
US (3) US10633657B2 (fr)
EP (2) EP4268891A3 (fr)
JP (1) JP6929269B2 (fr)
KR (2) KR20180080181A (fr)
CN (2) CN108135922A (fr)
AU (1) AU2016312590B2 (fr)
CA (1) CA2995996A1 (fr)
DK (1) DK3340993T5 (fr)
ES (1) ES2954151T3 (fr)
IL (1) IL257596B (fr)
MA (1) MA44836A (fr)
MX (1) MX2018002354A (fr)
RU (1) RU2742300C2 (fr)
WO (1) WO2017035319A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202466A (en) * 2016-12-05 2024-04-30 Regulus Therapeutics Inc Methods for treatment of polycystic kidney disease
EA201991360A1 (ru) * 2016-12-05 2019-11-29 Модифицированные олигонуклеотиды для лечения поликистозной болезни почек
EP3841220A1 (fr) 2018-08-23 2021-06-30 Roche Innovation Center Copenhagen A/S Biomarqueur de microarn-134
WO2024026354A2 (fr) * 2022-07-27 2024-02-01 The General Hospital Corporation Procédés et compositions destinés à être utilisés dans le traitement d'une maladie rénale polykystique récessive autosomique (arpkd)
WO2024254639A1 (fr) * 2023-06-16 2024-12-19 PYC Therapeutics Limited Compositions et méthodes de traitement d'une maladie rénale
WO2025110217A1 (fr) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 Agent prophylactique et/ou thérapeutique pour maladies kystiques rénales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648914A4 (fr) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
JPWO2007126150A1 (ja) * 2006-04-27 2009-09-17 国立大学法人名古屋大学 癌の新規治療用組成物
US20120283411A9 (en) * 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2008042973A2 (fr) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Formulations contenant un lipide
WO2008131191A2 (fr) * 2007-04-20 2008-10-30 Amgen Inc. Acides nucléiques hybridables avec des précurseurs des micro-arn de ceux-ci
WO2009143403A1 (fr) * 2008-05-23 2009-11-26 Targacept, Inc. Thérapie combinée de la gestion de l'hypertension
WO2014082644A1 (fr) * 2012-11-30 2014-06-05 WULFF, Peter, Samuel Arn circulaire destiné à l'inhibition de micro-arn
US10660890B2 (en) * 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
EP3105327A4 (fr) * 2014-02-12 2017-10-18 Thomas Jefferson University Compositions et procédés d'utilisation d'inhibiteurs de micro-arn
MY202466A (en) 2016-12-05 2024-04-30 Regulus Therapeutics Inc Methods for treatment of polycystic kidney disease
EA201991360A1 (ru) 2016-12-05 2019-11-29 Модифицированные олигонуклеотиды для лечения поликистозной болезни почек

Also Published As

Publication number Publication date
EP3340993B1 (fr) 2023-06-14
WO2017035319A8 (fr) 2021-03-11
US10633657B2 (en) 2020-04-28
ES2954151T3 (es) 2023-11-20
NZ740040A (en) 2024-07-26
DK3340993T5 (da) 2024-10-07
RU2018108206A3 (fr) 2020-01-14
US20200231971A1 (en) 2020-07-23
AU2016312590B2 (en) 2021-12-02
DK3340993T3 (da) 2023-08-21
MX2018002354A (es) 2018-12-10
RU2018108206A (ru) 2019-09-27
EP3340993A1 (fr) 2018-07-04
WO2017035319A1 (fr) 2017-03-02
CN108135922A (zh) 2018-06-08
CA2995996A1 (fr) 2017-03-02
JP6929269B2 (ja) 2021-09-01
EP4268891A3 (fr) 2024-01-24
KR20250049446A (ko) 2025-04-11
KR20180080181A (ko) 2018-07-11
IL257596A (en) 2018-04-30
EP4268891A2 (fr) 2023-11-01
IL257596B (en) 2022-08-01
CN114404440A (zh) 2022-04-29
RU2742300C2 (ru) 2021-02-04
US11168325B2 (en) 2021-11-09
US20220025372A1 (en) 2022-01-27
JP2018528945A (ja) 2018-10-04
US20190153442A1 (en) 2019-05-23
HK1256883A1 (en) 2019-10-04
AU2016312590A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
ZA201807286B (en) Angiotensinogen (agt) irna compositions and methods of use thereof
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
EA201792529A1 (ru) Ингибиторы тирозинкиназы
EA201890394A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
PH12018500578A1 (en) Methods of treating inflammatory diseases
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
EA201790867A1 (ru) Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
MX380677B (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
MX2017009038A (es) Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës